Regulatory and reimbursement pathways should consider indirect benefits in addition to direct health benefits when evaluating ...

Heart disease patients now have another treatment option. The U.S. Food and Drug Administration has approved Alnylam ...

One Source Nutrition, Inc. is voluntarily recalling all of its Vitality male enhancement capsules nationwide after an FDA ...

for one of Evofem’s FDA-approved products -- PHEXXI® (lactic acid, citric acid and potassium bitartrate). The product is a first-in-class hormone-free, on-demand prescription contraceptive ...

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

Last month, the U.S. Food and Drug Administration (the “FDA”) announced in a Declaratory Order the resolution of the shortage of semaglutide ...

Now that the shortage of semaglutide injection products has been resolved, the Food and Drug Administration (FDA) will restrict third parties ...

Q4 2024 Management View CEO Jennifer Ernst highlighted significant advancements, including the acquisition of exclusive worldwide rights to the Phase III immunomodulatory drug candidate Entolimod, ...

The FDA accepted a new drug application for SYD-101 to slow the progression of pediatric myopia and assigned a Prescription ...

The U.S. health secretary has vowed to close an FDA loophole that has allowed food companies to self-police the safety of new ...